Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020

被引：79

作者：

Wierda, William G. ^{[1
]}

Byrd, John C. ^{[2
,3
]}

Abramson, Jeremy S. ^{[4
]}

Bilgrami, Syed F. ^{[5
]}

Bociek, Greg ^{[6
]}

Brander, Danielle ^{[7
]}

Brown, Jennifer ^{[8
]}

Chanan-Khan, Asher A. ^{[9
]}

Chavez, Julio C. ^{[10
]}

Coutre, Steve E. ^{[11
]}

Davis, Randall S. ^{[12
]}

Fletcher, Christopher D. ^{[13
]}

Hill, Brian ^{[14
,15
]}

Kahl, Brad S. ^{[16
,17
]}

Kamdar, Manali ^{[18
]}

Kaplan, Lawrence D. ^{[19
]}

Khan, Nadia ^{[20
]}

Kipps, Thomas J. ^{[21
]}

Lim, Megan S. ^{[22
]}

Ma, Shuo ^{[23
]}

Malek, Sami ^{[24
]}

Mato, Anthony ^{[25
]}

Mosse, Claudio ^{[26
]}

Shadman, Mazyar ^{[27
]}

Siddiqi, Tanya ^{[28
]}

Stephens, Deborah ^{[29
]}

Sundaram, Suchitra ^{[30
]}

Wagner, Nina ^{[31
]}

Dwyer, Mary ^{[32
]}

Sundar, Hema ^{[32
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[3] Solove Res Inst, Columbus, OH USA

[4] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[5] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[6] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[7] Duke Canc Inst, Durham, NC USA

[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[9] Mayo Clin, Canc Ctr, Rochester, MN USA

[10] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[11] Stanford Canc Inst, Stanford, CA USA

[12] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[13] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[14] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[16] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[17] Washington Univ, Sch Med, St Louis, MO USA

[18] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA

[19] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[20] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[21] UC San Diego Moores Canc Ctr, San Diego, CA USA

[22] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[23] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[24] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[25] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[26] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[27] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[28] City Hope Natl Med Ctr, Duarte, CA USA

[29] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[30] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[31] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[32] Natl Comprehens Canc Network, Ft Washington, MD USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2020年 / 18卷 / 02期

关键词：

PREVIOUSLY UNTREATED PATIENTS; STEM-CELL TRANSPLANTATION; HIGH-DOSE METHYLPREDNISOLONE; MINIMAL RESIDUAL DISEASE; PHASE-II TRIAL; VARIABLE-REGION MUTATIONS; PROGRESSION-FREE SURVIVAL; CLINICAL END-POINTS; TERM-FOLLOW-UP; V-H GENES;

D O I：

10.6004/jnccn.2020.0006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in recent years because of the improved understanding of the disease biology and the development of novel targeted therapies. In patients with indications for initiating treatment, the selection of treatment should be based on the disease stage, patient's age and overall fitness (performance status and comorbid conditions), and cytogenetic abnormalities. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.

引用

页码：185 / 217

页数：33

共 199 条

[31] Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia [J].

Byrd, John C. ;

Flynn, Joseph M. ;

Kipps, Thomas J. ;

Boxer, Michael ;

Kolibaba, Kathryn S. ;

Carlile, David J. ;

Fingerle-Rowson, Guenter ;

Tyson, Nicola ;

Hirata, Jamie ;

Sharman, Jeff P. .

BLOOD, 2016, 127 (01) :79-86

[32] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Shaw, Yun ;

Bilotti, Elizabeth ;

Zhou, Cathy ;

James, Danelle F. ;

O'Brien, Susan .

BLOOD, 2015, 125 (16) :2497-2506

[33] Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study [J].

Cartron, Guillaume ;

de Guibert, Sophie ;

Dilhuydy, Marie-Sarah ;

Morschhauser, Franck ;

Leblond, Veronique ;

Dupuis, Jehan ;

Mahe, Beatrice ;

Bouabdallah, Reda ;

Lei, Guiyuan ;

Wenger, Michael ;

Wassner-Fritsch, Elisabeth ;

Hallek, Michael .

BLOOD, 2014, 124 (14) :2196-2202

[34] Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia [J].

Castro, J. E. ;

Sandoval-Sus, J. D. ;

Bole, J. ;

Rassenti, L. ;

Kipps, T. J. .

LEUKEMIA, 2008, 22 (11) :2048-2053

[35] Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia [J].

Castro, J. E. ;

James, D. F. ;

Sandoval-Sus, J. D. ;

Jain, S. ;

Bole, J. ;

Rassenti, L. ;

Kipps, T. J. .

LEUKEMIA, 2009, 23 (10) :1779-1789

[36] Tumor Flare Reaction Associated With Lenalidomide Treatment in Patients With Chronic Lymphocytic Leukemia Predicts Clinical Response [J].

Chanan-Khan, Asher ;

Miller, Kena C. ;

Lawrence, David ;

Padmanabhan, Swaminathan ;

Miller, Austin ;

Hernandez-Illatazurri, Francisco ;

Czuczman, Myron S. ;

Wallace, Paul K. ;

Zeldis, Jerome B. ;

Lee, Kelvin .

CANCER, 2011, 117 (10) :2127-2135

[37] Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Chanan-Khan, Asher A. ;

Zaritskey, Andrey ;

Egyed, Miklos ;

Vokurka, Samuel ;

Semochkin, Sergey ;

Schuh, Anna ;

Kassis, Jeannine ;

Simpson, David ;

Zhang, Jennie ;

Purse, Brendan ;

Foa, Robin .

LANCET HAEMATOLOGY, 2017, 4 (11) :E534-E543

[38] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia [J].

Chavez, Julio C. ;

Piris-Villaespesa, Miguel ;

Dalia, Samir ;

Powers, John ;

Turba, Elyce ;

Nodzon, Lisa ;

Komrokji, Rami ;

Sokol, Lubomir ;

Locke, Frederick L. ;

Lancet, Jeffrey ;

Sotomayor, Eduardo M. ;

Kharfan-Dabaja, Mohamed A. ;

Pinilla-Ibarz, Javier .

LEUKEMIA RESEARCH, 2016, 47 :78-83

[39] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[40] Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia [J].

Cheson, Bruce D. ;

Byrd, John C. ;

Rai, Kanti R. ;

Kay, Neil E. ;

O'Brien, Susan M. ;

Flinn, Ian W. ;

Wiestner, Adrian ;

Kipps, Thomas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (23) :2820-2822

← 1 2 3 4 5 6 7 8 9 10 →